IntroductionThe eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India.Case descriptionA total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment.Discussion and evaluationDrug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role.ConclusionManaging DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed.
[1]
C. Paramasivan,et al.
Drug resistance in tuberculosis in India.
,
2004,
The Indian journal of medical research.
[2]
N. Ford,et al.
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
,
2012,
The Lancet. Infectious diseases.
[3]
D. O’Brien,et al.
The ‘frozen state’ of drug‐resistant tuberculosis: notes from the field in Abkhazia
,
2011,
Internal medicine journal.
[4]
E. Pontali,et al.
Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India
,
2011,
PloS one.
[5]
Donna Neuberg,et al.
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
,
2003,
The New England journal of medicine.
[6]
S. Agarwal,et al.
Surveillance of drug resistance to anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa.
,
2005
.
[7]
J. Fitzgerald,et al.
Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
,
2009,
PloS one.
[8]
R. Venkatesan,et al.
Prevalence of acquired MDR-TB and HIV co-infection.
,
2002,
The Indian journal of chest diseases & allied sciences.
[9]
Florian T. Furtak.
Human Rights Watch (HRW)
,
2015
.
[10]
Evan W. Orenstein,et al.
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.
,
2009,
The Lancet. Infectious diseases.
[11]
V. Chadha.
Tuberculosis epidemiology in India: a review.
,
2005,
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.